Actelion moves for judgment against US antitrust case over Tracleer
MLex Summary: Actelion Pharmaceuticals moved for a summary judgment against US antitrust claims accusing it of delaying entry of a generic version of the hypertension drug Tracleer. “Plaintiff in this antitrust case...To view the full article, register now.
Already a subscriber? Click here to view full article